1 citations
,
March 2024 in “Journal of Cellular and Molecular Medicine” In this study, researchers found that 4-Octyl itaconate (4-OI) inhibited cisplatin-induced ferroptosis and protected auditory cells by activating the NRF2/HO-1 signaling pathway, suggesting a potential therapeutic approach for reducing hearing loss associated with cisplatin treatment.
May 2026 in “BMC Medicine” This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.
2 citations
,
December 2022 in “PNAS nexus” In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.
January 2025 in “RSC Pharmaceutics” Smart microneedles using advanced tech could improve psoriasis treatment.
1 citations
,
November 2024 in “Life” In this study, Desmodesmus pannonicus water extract demonstrated significant antioxidative properties, inhibited melanin production, promoted wound healing in human keratinocyte cells, and showed potential for hair growth enhancement in human follicle dermal papilla cells, suggesting its promise for future dermatological applications.